bioecon Member area
Technology · Biochemistry & industrial biotech / Specialty & fine chemicals

DNA-personalized skincare

Skincare formulated against a genetic or epigenetic read of the buyer's skin — a cheek swab typed for ageing-related variants, then matched to actives — sold either as a direct-to-consumer product line or as a white-label engine other beauty brands license.

Leisure, Welfare & Integration Maturity 4/9 Risk: medium Cosmetics US · EU · IN Science: why it works → verified 2026-08-18 · 5 Sources (0 independent)

1 · What it gives

The premise is narrow and testable: a handful of common variants influence how fast skin loses collagen, how strongly it responds to UV and oxidative stress, and how well it holds a barrier — so a product chosen against those variants should beat one chosen off a shelf. The commercial expression is a cheek swab returned by post, a report on a defined marker set, and either a bespoke formulation or a mapped regimen. Panel sizes are modest and disclosed: the SkinDNA laboratory test reads 16 genetic markers across five skin-ageing categories, Mapmygenome’s BeautyMap covers more than 40 skin and hair conditions, and LifeNome’s engine claims to analyse over 20,000 gene-ingredient interactions. Turnaround is measured in weeks, not days — six to eight weeks on some Australian panels — and pricing runs from roughly AU$129 for a report-only test to a full DNA analysis bundled with four personalised products.

The key directions of DNA-personalized skincare are:

  1. Dermatogenomic SNP panels (Genetic skin typing): a defined set of variants associated with collagen loss, elasticity, pigmentation, sensitivity and oxidative-stress response, read from a mouth swab. SkinDNA’s laboratory test examines 16 SNPs across five categories including firmness and elasticity, positioned to flag accelerated collagen loss before it is visible.
  2. Bespoke formulation from a genetic report (Made-to-genotype products): the report drives an actual product rather than advice. Nomige sells a DNA analysis with a skin report and four personalised products, and runs a reorder path for those products — a subscription shape rather than a one-off test.
  3. White-label personalisation engines (B2B beauty intelligence): the analytical layer licensed to other brands rather than sold to the consumer. LifeNome’s precision-beauty engine covers DNA, microbiome and epigenetic methylation data and is explicitly offered white-labelled, which is how most large beauty brands enter this space.
  4. Epigenetic ageing readouts (Methylation-based testing): a second measurement axis that changes over time, unlike genotype. Muhdo built its epigenetic supplement range on data from 70,000 individuals and publishes gene-level skin-health content, extending the model from fixed variants to modifiable methylation state.

Sectoral value chain#

[Swab kit] ──> [Sample collection] ──> [Genotyping/methylation] ──> [Report]
                                                 │
                                       (gene-ingredient rules)
                                                 │
                                                 ▼
[Reorder / retest] <─── [Formulation or regimen] <┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Panel designA marker set is selected from published skin-genetics associations and fixed as the product’s analytical scope.In: dermatogenomics literature, candidate SNPs, methylation sites.
Out: a disclosed panel of defined size and category structure.
Kit & samplingA buccal swab kit reaches the consumer with collection instructions and a return path to the laboratory.In: swab kit, consumer instructions, prepaid return.
Out: a labelled sample with usable DNA yield.
Laboratory analysisThe sample is genotyped for the panel, or assayed for methylation, in a contracted or in-house laboratory.In: buccal sample, genotyping array or methylation assay.
Out: raw variant or methylation calls.
InterpretationCalls are translated into category scores — firmness, pigmentation, sensitivity — against the vendor’s rule set.In: variant calls, association rules, lifestyle questionnaire.
Out: a per-category skin report.
Formulation or regimenThe report drives either a bespoke formulation or a mapped selection from an existing range.In: category scores, active-ingredient library, formulation constraints.
Out: personalised product set or recommended regimen.
Reorder & retestThe relationship continues through product replenishment and, for epigenetic tests, periodic retesting.In: usage cadence, methylation drift for epigenetic products.
Out: repeat revenue and an updated recommendation.

Cross-cutting technologies of the sector:

  • Buccal-swab sample logistics (At-home DNA collection): mouth-swab kits and postal return, the same consumer-genomics infrastructure that made ancestry testing a mass product, reused for a cosmetic endpoint.
  • Gene-ingredient rule engines (Ingredient matching): the mapping layer between a variant call and an active — the actual intellectual property in this category, and where LifeNome’s claimed 20,000-plus interaction set sits.
  • Methylation clocks for skin (Epigenetic readout): assays that measure a modifiable biological state rather than a fixed genotype, allowing a retest to show change and turning a one-off purchase into a monitored one.

2 · What it replaces 3 · matched by industry

D1E–Fermentation cosmetic ingredients instead of shark-liver squalene, rooster-comb hyaluronic acid and animal collagen
Replaces: Shark-liver oil squalene (deep-sea shark fisheries); hyaluronic acid from rooster combs; bovine/porcine collagen extracts (and their …
COSM
D3E2Biodegradable scrub particles and exfoliants instead of polyethylene microbeads
Replaces: Polyethylene (and PP/PET/PMMA) microbeads in rinse-off cosmetics: face/body scrubs, toothpastes, shower gels; glitter (polyester/alu …
COSM
D1E–Biosurfactant and APG cleansing — sophorolipids, rhamnolipids, alkyl polyglucosides — instead of petrochemical SLES/SLS
Replaces: Petrochemical anionic surfactants (SLES/SLS) and their ethoxylated feedstock chain (1,4-dioxane contamination risk at trace levels, …
COSM

3 · How to implement 6 steps

  1. 1
    Panel definition
    A marker set is fixed from published skin-genetics associations and grouped into consumer-legible categories — the SkinDNA panel’s five categories over 16 SNPs is typical of the scale. Fixing the panel also fixes the claim, which is why vendors publish the count.
  2. 2
    Swab kit & collection
    A buccal swab kit ships with instructions and a prepaid return. The step is commodity consumer-genomics logistics, and its failure mode is a low-yield or contaminated sample rather than anything analytical.
  3. 3
    Laboratory genotyping
    The sample is typed for the panel or assayed for methylation, usually in a contracted laboratory. Turnaround is the visible cost: six to eight weeks is quoted on some Australian skin panels, an eternity by the standards of consumer beauty.
  4. 4
    Report generation
    Variant calls become per-category scores against the vendor’s rule set, often combined with a lifestyle questionnaire. This is where a genotype becomes a recommendation, and where two vendors reading the same sample can legitimately differ.
  5. 5
    Formulation or regimenFormulation & blending
    The report either drives a bespoke formulation — Nomige’s model, a DNA analysis bundled with four personalised products — or maps to items in an existing range, which is the lower-cost route most licensing brands take.
    Who can do this step matched automatically
    SyAqua Group Thailand
    “vannamei genetics (broodstock, nauplii, and post-larvae) built on genomic selection/marker-assisted selection plus quantitative genetics (BLUP), with disease resistance screening …”
    ✓ GMP ✓ ISO 9001
    “Ice Cream Premix Powder”
    ✓ GMP ✓ ISO 9001 7,500 MT/ industrial scale
    “Recent expansions and new facilities across процесses: MEG production growth (up to 200,000 MTPA), EO purification, ethoxylate, sulphation, formulation plants, and …”
    500,000 tons pilot scale
    “It refines sugar (including refined white sugar, golden brown sugar, fine granulated sugar and invert sugar syrup), produces bio-based chemicals/biotech outputs (alcohol, …”
    3000 tons
    “Quality and services: ISO 9001 and ISO 22000 certified; extensive experience (over 15 years) with professional granulation services to improve bulk density for capsules/tablets; …”
  6. 6
    Reorder & retest
    Genotype-based products monetise through replenishment of the personalised formulation; epigenetic products add periodic retesting, since methylation state moves and a second measurement can show it.

4 · Who delivers

Matched suppliers (matched automatically)

L'OréalFranceProduceractive
Jiangsu TrautecChinaProduceractive
ORF GeneticsIcelandProduceractive
Giant Biogene HoldingChinaDistributoractive
Lofoten Seaweed Company ASNorwayProduceractive
Quantec LtdNew ZealandProduceractive
TurtleTreeSingaporeProduceractive
CRUST GroupSingaporeDistributoractive
AGC BiologicsUnited StatesProduceractive

In the services and supply catalogue 1 · paid service

Contract manufacturing (CMO/CDMO/toll)

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Nomige🇧🇪 BelgiumDNA analysis plus personalised productsDermatogenomics-led bespoke formulationcommercial
LifeNome🇺🇸 USAPrecision-beauty engineWhite-label DNA, microbiome and methylationcommercial
SkinDNA🇦🇺 AustraliaSkin DNA laboratory test16 SNPs across five ageing categoriescommercial
Mapmygenome🇮🇳 IndiaBeautyMapSkin and hair panel, 40+ conditionscommercial
Muhdo🇬🇧 United KingdomEpigenetic testing and supplementsMethylation readout, 70,000-person datasetcommercial

5 · Rules & route to market

Route into Russia / EAEU: COSM · EAEU conformity bodies (Rospotrebnadzor for SGR)
declaration (SGR for some categories)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

The US pattern is business-to-business: the technology is sold to beauty brands as an engine rather than to consumers as a brand, which is what lets a small team reach a mass market.

White-label precision-beauty engines, multi-omic personalisation, small teams behind large brands#

  • LifeNome: founded in 2016 and headquartered in New York with a team in the single digits and $5.1 million raised across two rounds, it sells a precision-beauty engine covering DNA, microbiome and epigenetic methylation, analysing gene-ingredient interactions and offering white-labelled reports that partner brands ship under their own name.
  • Multi-omic framing: the US vendors have largely moved past genotype alone, folding microbiome and methylation data into the same recommendation, which broadens the claim surface and also the evidentiary burden.
  • Claim discipline: because the endpoint is cosmetic rather than medical, marketing sits under FTC substantiation rules rather than a regulatory approval process, which is the constraint that shapes how these products describe themselves.

European Union

Europe is where the direct-to-consumer product form is strongest: a founder-led brand selling a genetic analysis bundled with the creams it prescribes.

Founder-led DNA cosmetics brands, bundled analysis and product, epigenetics as the adjacent market#

  • Nomige: a Belgian brand founded by Dr Barbara Geusens on dermatogenomics research, selling a DNA analysis with a skin report and four personalised products, plus a day-cream range addressed to specific concerns — stress protection, barrier repair, redness, pigmentation — and a reorder path for the personalised formulations.
  • Muhdo: a UK epigenetics company whose supplement range is informed by data from 70,000 individuals and which publishes gene-level skin-health material, representing the methylation-based rather than genotype-based end of the same market.
  • Cosmetics framing: under Regulation 1223/2009 these remain cosmetic products, so the genetic report is a selection aid and not a therapeutic claim — a boundary the credible vendors are careful to keep.

China

China is a large personalised-cosmetics market, but no domestic DNA-skincare vendor cleared confirmation on this screen, so the region is described rather than tabled.

Personalisation without genotyping, regulatory caution on genetic data, unconfirmed vendor set#

  • Different personalisation route: the mainstream Chinese approach to bespoke skincare leans on instrument-based skin analysis and AI imaging in retail settings rather than on a mailed DNA sample, so the buyer journey does not pass through a genotyping laboratory.
  • Genetic-data governance: human genetic resources are tightly regulated in China, which raises the compliance cost of a consumer service built on collecting and processing DNA for a cosmetic purpose.
  • Screening limit: searches for 皮肤基因检测 and 定制护肤 returned no vendor that could be confirmed as a merchant of a DNA-based skincare product, so no Chinese row is claimed here.

6 · Money: tenders & grants

7 · Tech stack & innovations

Three layers stack up, and only the middle one is genuinely hard: collection is commodity, laboratory work is contracted, and the interpretation rules are the product.

  1. Panel selection and disclosure (SNP panel design):
    • Panels are deliberately small and named — 16 markers in five categories on the SkinDNA test, 40-plus conditions on Mapmygenome’s BeautyMap — because a defined scope is easier to substantiate than an open-ended genomic claim.
    • Categories map to concerns a buyer already recognises: firmness and elasticity, pigmentation, sensitivity, oxidative stress, so the report lands as advice rather than as data.
  2. Gene-ingredient rule engines (Interpretation layer):
    • This is where the differentiation lives. LifeNome’s engine is built around gene-ingredient interactions at a claimed scale of more than 20,000, which is the asset a licensing beauty brand is actually buying.
    • The same layer determines whether the output is a bespoke formulation, as at Nomige, or a mapped selection from an existing catalogue — a formulation decision as much as an analytical one.
  3. Methylation as a second axis (Epigenetic testing):
    • Genotype does not change, so a genotype-based product can only be sold once; methylation does change, which supports retesting and a monitoring relationship. Muhdo built its range on that distinction with a 70,000-individual dataset behind it.
    • It also shifts the claim from predisposition to current state, which is a stronger consumer proposition and a correspondingly higher evidentiary bar.

Sources 5 · 0 independent · 5 producer sites

Producers' own sites 5

  1. Nomige producer checked 2026-07-30 · link not kept
  2. Lifenome producer checked 2026-03-23 · link not kept
  3. Skindna producer checked 2025-11-02 · link not kept
  4. Mapmygenome producer checked 2026-06-04 · link not kept
  5. Muhdo producer checked 2026-04-30 · link not kept